Global Rheumatoid Arthritis Drugs Market – Snapshot

Rheumatoid arthritis is an autoimmune disorder that causes pain and inflammation in the joints. In this disease, the immune system mistakenly affects the joints, causing inflammation and pain in the joints throughout the body. Rheumatoid arthritis disease mostly affects the joints of the hand, wrists, elbows, knees, and ankles. Since rheumatoid arthritis also affects the cardiac and respiratory system, it is called a systemic disease. It usually affects the geriatric population, and the prevalence is higher in females as compared to males. Rheumatoid arthritis is also called a musculoskeletal disease, since it causes severe pain and deformity in one or more areas of the musculoskeletal system and in some indications, it exhibits symptoms of swelling, redness, and warmth in the affected areas.

rheumatoid arthritis drugs

In 2016, the global market for rheumatoid arthritis drugs was valued at US$ 19597.43 Mn. It is expected to expand at a CAGR of 2.96% from 2018 to 2026.

Several therapeutics and medication have been developed in recent years, to relieve and treat the symptoms of rheumatoid arthritis. Most commonly used drugs are disease modifying anti-rheumatic drugs (DMARDs), Nonsteroidal anti-inflammatory drugs (NSAID’s), corticosteroids, and biologic drugs. NSAIDs are widely utilized for the symptomatic treatment of rheumatic disorders. DMARDs are considered as the gold standard for the treatment of moderate to severe rheumatoid arthritis. Biologics account for a prominent market share, in terms of revenue, due to the considerably high cost of these medicines.

The global rheumatoid arthritis drugs market can be segmented based on drug type, distribution channel, and geography. Furthermore, in terms of drug type, the market can be divided into disease-modifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologic response modifiers (biologics). The biologics segment is likely to account for a leading share of the global rheumatoid arthritis market in terms of revenue, during the forecast period, owing to the wide usage of drugs in severe rheumatoid disease. Biotechnological research and developments in rheumatoid arthritis drugs are estimated to boost the biologic drugs segment during the forecast period. Based on distribution channel, the market can be segmented into hospital pharmacy, retail pharmacy and online pharmacy. The hospital pharmacy segment is estimated to expand at a prominent growth rate during the forecast period, owing to the increase in number of hospitals and rise in preference of the geriatric patient population to undergo treatment at hospitals.

In terms of geography, the global rheumatoid arthritis drugs market in Asia Pacific is likely to expand at a high CAGR between 2018 and 2026. Increase in the incidences of rheumatoid arthritis disease is projected to fuel the market in the region during the forecast period. The market in Asia Pacific is projected to witness high growth during the forecast period, due to increasing health care expenditure in the region. Moreover, low cost of manufacturing in China and India has resulted in the rise in the production facilities, attracting pharmaceutical and biotechnological giants to Asia Pacific from across the world.

A majority of rheumatoid arthritis drug products are being manufactured by key players covered in this report such as AbbVie, Inc., Janssen Biotech, Inc., Amgen, Inc., Pfizer, Inc., Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company. The market leaders in this industry have established their position in the market and enjoy brand loyalty among customers. These manufacturers have a wide product range to offer and have an extensive distribution system across the world. Additionally, the emerging markets in Asia are witnessing the entry of small players. However, stringent regulatory framework and high quality standards set by the market leaders are likely to restrain the speed of market penetration by new entrants.

Global Rheumatoid Arthritis Drugs Market: Overview

This report on the rheumatoid arthritis drugs market analyzes the current and future scenario of the global market. Rise in geriatric population, high prevalence of rheumatoid arthritis, and increase in patient preference for biological origin drugs are major drivers of the global rheumatoid arthritis drugs market.

The rheumatoid arthritis drugs market report comprises an executive summary, which includes a market synopsis that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug type, distribution channel, and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. Additionally, the section comprises competitive matrix and company profiles with business overview in order to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, in terms of geography, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global rheumatoid arthritis drugs market.

Global Rheumatoid Arthritis Drugs Market: Key Segments

The global rheumatoid arthritis drugs market can be segmented based on rheumatoid arthritis drug type, distribution channel, and geography. Furthermore, in terms of drug type, the market can be divided into disease-modifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologic response modifiers (Biologics). The biologics segment is likely to account for a leading share of the global rheumatoid arthritis market during the forecast period, owing to wide usage of these drugs in moderate to severe disease condition. Based on distribution channel, the market can be segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The market size and forecast for each of these segments have been provided for the period from 2017 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Rheumatoid Arthritis Drugs Market: Regional Outlook

Based on geography, the global rheumatoid arthritis drugs market has been categorized into five major regions, and the key countries in the respective region are: North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, GCC countries, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2018 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global rheumatoid arthritis drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players operating in the global rheumatoid arthritis drugs market include Pfizer, Inc., Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company.

The global rheumatoid arthritis drugs market has been segmented as given below:

  • Global Rheumatoid Arthritis Drugs Market Revenue, by Drug Type, 2016–2026
    • Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
    • Corticosteroids
    • Disease Modifying Anti-rheumatic Drugs (DMARDs)
    • Biologic Response Modifiers (Biologics)
  • Global Rheumatoid Arthritis Drugs Market Revenue, by Distribution Channel, 2016–2026
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Global Rheumatoid Arthritis Drugs Market Revenue, by Geography, 2016–2026
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • Italy
      • France
      • Spain
      • Rest of Europe
    • Asia Pacific
      • India
      • China
      • Japan
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • GCC countries
      • South Africa
      • Rest of Middle East & Africa
.